Stemline Therapeutics, Inc. (STML)
(Delayed Data from NSDQ)
$15.33 USD
+0.25 (1.66%)
Updated May 3, 2019 04:00 PM ET
After-Market: $15.33 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
[STML]
Reports for Purchase
Showing records 1 - 20 ( 255 total )
Industry: Medical - Biomedical and Genetics
Dropping Coverage Due to Announced Acquisition
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Menarini Acquires Stemline; Downgrade to Neutral; Lowering PT to $12.50
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
DOWNGRADING to NEUTRAL, Menarini to Acquire STML
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Industry: Medical - Biomedical and Genetics
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended March 27
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Industry: Medical - Biomedical and Genetics
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended March 20
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Industry: Medical - Biomedical and Genetics
From Underneath The Rubble Sing a Rebel Song
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
4Q and Full-Year 2019 Financial Results Reported; Reiterate Buy; Lowering PT to $18
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
ELZONRIS Bouncing Around, But Upside From These Levels
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Industry: Medical - Biomedical and Genetics
Positive Pivotal XPO1 Inhibitor Data Bolster SL-801 Prospects; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
Weekly Retail Sales Tracker for Hem. Malignancies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Industry: Medical - Biomedical and Genetics
Weekly Retail Sales Tracker for Hem. Malignancies
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
4Q19 Top-Line Revenue Disappoints; Reiterate Buy; Reducing PT to $20
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Preliminary 4Q19; Decreasing PT on Decelerating ELZONRIS Launch
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Industry: Medical - Biomedical and Genetics
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended January 3 2020
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Industry: Medical - Biomedical and Genetics
ELZONRIS Clinical Data in Myelofibrosis and Multiple Myeloma Presented; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
3Q19; ELZONRIS Launch Going Just Fine, Myelofibrosis Update Next at ASH
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D